Selank (Selanc; TP-7) is a GABAA receptor modulator with anxiolytic activity. Selank allosterically modulates the specific binding of GABA to GABAA receptors and alters the affinity of endogenous ligands for these receptors. Selank reduces elevated anxiety levels, attenuates stress-induced exacerbation of anxiety, and produces a synergistic anxiolytic effect with diazepam. Selank can be used in the research of anxiety disorders [1].
In Vivo, Selank (300 μg/kg; i.n.; once daily; 14 days) minimizes test-induced anxiety-related behavioral deterioration in non-stressed rats, with no statistically significant changes in measured anxiety or locomotor activity parameters relative to pre-treatment levels[1]. Selank (300 μg/kg; i.n.; once daily; 14 days) significantly mitigates stress-induced anxiety-related behavioral deterioration in UCMS-exposed rats compared to saline-treated controls[1].
References:
[1]. Kasian A, et al. Peptide Selank Enhances the Effect of Diazepam in Reducing Anxiety in Unpredictable Chronic Mild Stress Conditions in Rats. Behav Neurol. 2017;2017:5091027.
In Vivo, Selank (300 μg/kg; i.n.; once daily; 14 days) minimizes test-induced anxiety-related behavioral deterioration in non-stressed rats, with no statistically significant changes in measured anxiety or locomotor activity parameters relative to pre-treatment levels[1]. Selank (300 μg/kg; i.n.; once daily; 14 days) significantly mitigates stress-induced anxiety-related behavioral deterioration in UCMS-exposed rats compared to saline-treated controls[1].
References:
[1]. Kasian A, et al. Peptide Selank Enhances the Effect of Diazepam in Reducing Anxiety in Unpredictable Chronic Mild Stress Conditions in Rats. Behav Neurol. 2017;2017:5091027.